Skip to main content

Table 2 Univariate and multivariate logistic regression analysis in estimation set

From: Development of a decision flowchart to identify the patients need high-dose vancomycin in early phase of treatment

Characteristics

All patients

(n = 146)

High-dose

(n = 49)

Standard-dose

(n = 97)

P value

Univariate

Multivariate

Male, n (%)

96 (65.8)

31 (63.3)

65 (67.0)

0.653

Age [years]a

60.7 ± 15.0

52.0 ± 15.2

65.0 ± 12.9

< 0.001

0.020

Body weight [kg]a

58.3 ± 12.9

63.1 ± 13.7

55.8 ± 11.9

0.002

–

BMI [kg/m2]a

21.9 ± 3.9

23.1 ± 4.3

21.3 ± 3.5

0.011

–

SCr [mg/dL]a

0.69 ± 0.23

0.62 ± 0.19

0.73 ± 0.24

0.003

–

eCCr [mL/min]a

95.9 ± 43.8

123.0 ± 40.4

82.2 ± 38.9

< 0.001

0.001

Initial VCM dose, nb

   

< 0.001d

 > 2 g/day

11 (10/1/0)

11 (10/1/0)

0 (0/0/0)

 

 =2 g/day

108 (0/107/1)

34 (0/34/0)

74 (0/73/1)

 

 < 2 g/day

27 (1/19/7)

4 (1/2/1)

23 (0/17/6)

 

Day until first TDM [days]c

4 (2–7)

3 (2–7)

4 (3–6)

0.213e

First Ctrough [μg/mL]a

 All patients

13.0 ± 6.0

8.2 ± 3.8

15.5 ± 5.5

< 0.001f

 > 2 g/day

13.3 ± 3.5

13.3 ± 3.5

–

–

 =2 g/day

13.3 ± 6.1

6.8 ± 2.1

16.3 ± 4.9

< 0.001f

 < 2 g/day

11.8 ± 6.7

5.8 ± 3.5

12.8 ± 6.5

0.047f

BE conducted, n (%)

59 (40.4)

33 (67.3)

26 (26.8)

< 0.001d

  1. aData are shown as mean ± standard deviation (SD)
  2. bNumbers in parentheses indicate the number of patients with dosing intervals of 8 h, 12 h, and others from the left, respectively
  3. cData are shown as median (range)
  4. dχ2-test
  5. eMann–Whitney U-test
  6. fUnpaired student’s t-test
  7. BMI body mass index, SCr serum creatinine, eCCr estimated creatinine clearance, Ctrough trough concentration of VCM, BE Bayesian estimation